Ara Parseghian Medical Research Foundation
A Goal For Life
The Faces of NPC
Quote from ara

Video 1


Online Videos

YouTube-Celebrating Ara's 90th B'Day

Survivor Tales
Legacy of Hope part 1

Legacy of Hope part 2

University of Notre Dame: Fighting For The Lives Of Children

See More Videos

Niemann-Pick Type C is a genetic, cholesterol storage disorder that primarily strikes children with death occurring before or during adolescence. There is also an adult onset form of the disease.

 The Ara Parseghian Medical Research Foundation is a non-profit organization dedicated to funding medical research projects to find a treatment for Niemann-Pick Type C (NP-C) disease. The Parseghian Foundation is named in honor of Ara Parseghian, the much beloved and well-known Notre Dame Football Coach, whose three youngest grandchildren were diagnosed with NP-C in 1994. 

Medical research is the key to saving the lives of all those around the world afflicted with Niemann-Pick disease. You can help by donating to the Ara Parseghian Medical Research Foundation. Thank you.

Donate Now

Upcoming EventsMarch 12, 7:00pm-3rd Annual Parseghian Cup Rugby Match

Read MoreRead  More

APMRF Newsletter

A Goal for Life - The Newsletter of the Ara Parseghian Medical Research Foundation.

Read MoreRead More


A Message from Ara

Our hearts are broken. The pain of losing our three youngest grandchildren is almost unbearable.

Ara Message
Read MoreRead More


Get Involved


Help Build A Research Resource for Niemann Pick Disease

The Coriell Institute for Medical Research supports NPC research by making a variety of cell lines and DNA samples available to researchers through the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository.


Niemann-Pick Type C (NP-C) disease Research News


One Family’s Fighting Spirit - Read The Parseghian Family Story


More About Niemann-Pick - Read an overview of the disease diagnosis, symptoms and treatment.


Research on NPC
-Annual Scientific Conference
-Scientific Advisory Board

-Articles on Potential Therapies

-NIH Clinical Trial Begins for NPC


Contact us about getting involved in the fight against Niemann-Pick disease.

Donate Now Sign Me Up


Help raise money to fight NP-C by attending the 3rd annual Parseghian Cup Rugby Match


NIH teams with industry to develop treatments for Niemann-Pick Type C disease

January 7, 2015


Researchers from the National Institutes of Health have entered into an agreement with biotechnology company Vtesse, Inc., of Gaithersburg, Maryland, to develop treatments for Niemann-Pick disease type C (NPC) and other lysosomal storage disorders.


Researchers at the National Center for Advancing Translational Sciences (NCATS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both parts of NIH, will conduct studies on NPC and other lysosomal storage disorders with funding provided by Vtesse.


Read More

National Institutes of Health Announcement- Hope for NPC Patients


We are pleased to inform the NPC community of an upcoming clinical trial at the NIH to study the safety and tolerability of vorinostat in adults with Niemann-Pick disease, type C1. We plan to begin enrolling patients in September 2014.

This clinical trial is an open label study for 12 patients. “Open label” means that every patient will get vorinostat. There is no placebo, or sugar pill, in this study. Patients will come to the NIH for a total of 3 visits - at baseline, 3 months and at 6 months for this trial. Each visit will last for about 7-10 days. Patients will start taking the study drug while they are at the NIH and will continue taking the study drug when they return home. They will also need to have blood drawn for safety labs every two weeks between visits while they are at home. After the 6 month visit, they will stop taking the study drug and they will be done with the trial.

Vorinostat is a pill that is taken by mouth. The purpose of this study is to test the safety and tolerability of vorinostat when it is given to adults with NPC1. Patients will have blood drawn and will have a lumbar puncture (spinal tap) to collect spinal fluid at each visit to measure how much of the drug is absorbed. Patients will also have tests of hearing, speech, swallowing and movement.

Read More


Helping KidsSadly, the Parseghian family has lost Michael, Marcia and Christa to Niemann-Pick Type C disease.  Their hearts will be forever broken.

Their resolve, however, to continue the fight against NP-C disease is not broken.  The Parseghians and thousands of volunteers and friends across the US and around the world are raising funds and pushing medical research so that a treatment can be found.

Please help us in this valiant effort so that everyone afflicted with Niemann-Pick around the world can live to realize their hopes and dreams. Thank you.


Hope for KidsWe Need Your Help!
.Angel Twins
.BReaK Thru Fund
.Fight For Jessica
.Help Kevin
.Hadley Hope
.See More >>

Vorinostat NIH Trial Announcement

© 2008 Ara Parseghian Medical Research Foundation
Mailing Address: 4729 E Sunrise Dr. #327, Tucson, Arizona 85718-4535,

Phone: (520) 577-5106 Fax: (520) 577-5212, E-Mail: